Business
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
President, Founder and Chief Executive Officer to participate in “AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape” fireside chat on March 14,
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nPresident, Founder and Chief Executive Officer to participate in “AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape” fireside chat on March 14, 2022 at 11:00 am ET\n\nLeadership team to participate in fireside chat at Oppenheimer’s 32nd Annual Virtual Healthcare Conference on March 15, 2022 at 1:20 pm ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.\n\nA webcast of both events will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.\n\nConference Details:\n\n\n\nEvent:\n\n\n\n \n\n\n\n \n\n\n\nOppenheimer 32nd Annual Virtual Healthcare Conference\n\n\n\n\n\nDate:\n\n\n\n \n\n\n\n \n\n\n\nMarch 14, 2022\n\n\n\n\n\nTime:\n\n\n\n \n\n\n\n \n\n\n\n11:00 am ET\n\n\n\n\n\nFormat:\n\n\n\n \n\n\n\n \n\n\n\nFireside chat: AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape\n\n\n\n\n\nParticipants:\n\n\n\n \n\n\n\n \n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nDate:\n\n\n\n \n\n\n\n \n\n\n\nMarch 15, 2022\n\n\n\n\n\nTime:\n\n\n\n \n\n\n\n \n\n\n\n1:20 pm ET\n\n\n\n\n\nFormat:\n\n\n\n \n\n\n\n \n\n\n\nFireside chat\n\n\n\n\n\nParticipants:\n\n\n\n \n\n\n\n \n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene T...